Hartnett v. Physicians Choice Laboratory Services, LLC

CourtDistrict Court, W.D. North Carolina
DecidedFebruary 5, 2020
Docket3:17-cv-00037
StatusUnknown

This text of Hartnett v. Physicians Choice Laboratory Services, LLC (Hartnett v. Physicians Choice Laboratory Services, LLC) is published on Counsel Stack Legal Research, covering District Court, W.D. North Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hartnett v. Physicians Choice Laboratory Services, LLC, (W.D.N.C. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF NORTH CAROLINA CHARLOTTE DIVISION CIVIL ACTION NO. 3:17-CV-00037-KDB-DCK

UNITED STATES OF AMERICA, EX REL., TARYYN HARTNETT AND DANA SHOCHED,

Plaintiffs,

v. ORDER

PHYSICIANS CHOICE LABORATORY SERVICES, LLC; DOUGLAS SMITH, PHILIP MCHUGH AND MANOJ KUMAR,

Defendants.

THIS MATTER is before the Court on Defendant Philip McHugh’s Motion to Dismiss Complaint in Intervention (Doc. No. 73). The Court has carefully considered this motion and the parties’ related briefs and exhibits, and it is ripe for decision. For the reasons discussed below, the Court finds that Plaintiff United States of America (the “United States” or “Government”) has, in the context of this motion to dismiss pursuant to Federal Rules of Civil Procedure 9(b) and 12(b)(6), adequately pled its asserted False Claims Act (“FCA”) and related state law claims. Therefore, the Court will DENY the motion. I. LEGAL STANDARD A motion to dismiss under Federal Rule of Civil Procedure 12(b)(6) for “failure to state a claim upon which relief can be granted” tests whether the complaint is legally and factually sufficient. See Fed. R. Civ. P. 12(b)(6); Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009); Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007); Coleman v. Md. Court of Appeals, 626 F.3d 187, 190 (4th Cir. 2010), aff'd, 566 U.S. 30 (2012). A court need not accept a complaint's “legal conclusions, elements of a cause of action, and bare assertions devoid of further factual enhancement.” Nemet Chevrolet, Ltd. v. Consumeraffairs.com, Inc., 591 F.3d 250, 255 (4th Cir. 2009). The court, however, “accepts all well-pled facts as true and construes these facts in the light most favorable

to the plaintiff in weighing the legal sufficiency of the complaint.” Id. Construing the facts in this manner, a complaint must contain “sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its face.” Id. Ordinarily, a plaintiff need only make “a short and plain statement of the claim showing that the pleader is entitled to relief.” Fed. R. Civ. P. 8(a)(2). Rule 9 of the Federal Rules of Civil Procedure creates an exception to this notice pleading standard for “Pleading Special Matters,” requiring, inter alia, that “[i]n alleging fraud or mistake, a party must state with particularity the circumstances constituting fraud or mistake.” Fed. R. Civ. P. 9(b). Claims under the FCA must meet the more stringent “particularity” pleading requirements of Rule 9(b). See United States ex

rel. Ahumada v. NISH, 756 F.3d 268, 280 (4th Cir.2014). Specifically, for an FCA claim, Rule 9(b) requires that “an FCA plaintiff must, at a minimum, describe the time, place, and contents of the false representations, as well as the identity of the person making the misrepresentation and what he obtained thereby.” United States ex rel. Wilson v. Kellogg Brown & Root, Inc., 525 F.3d 370, 379 (4th Cir.2008). However, “knowledge, and other conditions of a person’s mind may be alleged generally.” See Fed. R. Civ. P. 9(b). The Fourth Circuit has articulated four purposes of the Rule 9(b) pleading standard: (1) to put defendants on notice of the conduct at issue so that defendants have sufficient information to answer and defend themselves; (2) to protect defendants from frivolous lawsuits; (3) to avoid fraud actions where the relevant facts are not known prior to discovery; and (4) to protect defendants from negative consequences of being named as defendants in fraud actions, such as damage to their goodwill and reputation. See Maguire Fin., LP v. PowerSecure Int'l, Inc., 876 F.3d 541, 546 (4th Cir. 2017); Harrison v. Westinghouse Savannah River Co., 176 F.3d 776, 784 (4th Cir. 1999). II. FACTS AND PROCEDURAL HISTORY1

Defendant Physicians Choice Laboratory Services, LLC (“PCLS”) is an independent diagnostic laboratory specializing in urine drug testing (“UDT”). Defendants Douglas Smith and Philip McHugh are two of the three founders, and current owners, of PCLS. The United States alleges that PCLS has grown its business by convincing physicians to order UDTs for their patient populations regardless of whether the tests were medically necessary for each patient. Further, and more directly relevant to these proceedings, the Government contends that in addition to aggressive marketing practices, Defendants engaged in several illegal schemes to provide remuneration to doctors to induce them to refer tests to the laboratory in violation of the Anti- Kickback Statute. 42 U.S.C. § 1320a-7b(b) (the “AKS”).

The United States alleges in detail three specific schemes that McHugh and the other defendants planned and implemented that allegedly violated the AKS and caused fraudulent claims to be submitted to Medicare. First, McHugh allegedly induced physicians to refer tests to PCLS by providing office equipment and associated services to physicians in exchange for sending their referrals to PCLS. Doc. No. 38 at ¶¶ 159-219. Second, McHugh allegedly entered an illegal contract to pay co-defendant Manoj Kumar (“Kumar”) to send referrals to PCLS from two physician practices that Kumar managed. Id. at 220-232. Finally, McHugh allegedly made large loans to two physicians in exchange for their referrals to PCLS. Id. at 233-254. PLCS then

1 The facts described below are taken from the Complaint of the United States, Doc. No. 38. allegedly submitted claims to Medicare for the testing services provided to the patients referred to PCLS as a result of the alleged kickback schemes. On January 7, 2014, a qui tam complaint generally relating to these and/or other allegations was filed in the Eastern District of Tennessee under the qui tam provisions of the False Claims Act (the “Tennessee Complaint”) against fifty (50) defendants, including defendant McHugh. On

November 10, 2014, relators Taryn Hartnett and Dana Schoched filed a qui tam complaint in the Middle District of Florida (the “Florida Complaint”), against several defendants but not including McHugh. Both the Tennessee and Florida Complaints were transferred to this Court in January 2017 and later consolidated into one action (Doc. No. 37).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Starks
157 F.3d 833 (Eleventh Circuit, 1998)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
United States v. McClatchey
217 F.3d 823 (Tenth Circuit, 2000)
Coleman v. Maryland Court of Appeals
626 F.3d 187 (Fourth Circuit, 2010)
Coleman v. Court of Appeals of Maryland
132 S. Ct. 1327 (Supreme Court, 2012)
Nemet Chevrolet, Ltd. v. Consumeraffairs. Com, Inc.
591 F.3d 250 (Fourth Circuit, 2009)
US ex rel. Mike Ahumada v. NISH
756 F.3d 268 (Fourth Circuit, 2014)
Bluewave Healthcare v. United States
853 F.3d 131 (Fourth Circuit, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
Hartnett v. Physicians Choice Laboratory Services, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hartnett-v-physicians-choice-laboratory-services-llc-ncwd-2020.